TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12501759
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg twice a day for eight weeks
Study: 9798587
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg keliximab
Study: 9798587
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg keliximab
Study: 9798587
Drug: 3.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg keliximab
Study: 7619674
Drug: Romazarit 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romazarit 200 mg every 12 h for up to 24 weeks
Study: 7619674
Drug: Romazarit 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romazarit 450 mg every 12 h for up to 24 weeks
Study: 31698293
Drug: Medication error
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication error encouragement training (MEET)
Study: 9458824
Drug: BNP infusion
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP infusion (1, 2, or 4 pmol.kg‐1.min‐1 for 60 min)
Study: 8058542
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine (0.8 mg/kg)
Study: 8058542
Drug: Submucosal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal meperidine (0.8 mg/kg)
Study: 8058542
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine (0.8 mg/kg)
Study: 8058542
Drug: Oral meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meperidine (1.4 mg/kg)
Study: 2404435
Drug: HBM clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM clinical intervention administered in the ED
Study: 28786220
Drug: No androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No androgen deprivation therapy (Control)
Study: 26454361
Drug: Dupilumab 100
Normalized name: DUPILUMAB 100MG/0.67ML INJ,SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 100 mg every 4 weeks
Study: 27268421
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg once weekly
Study: 27268421
Drug: Dupilumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (all doses)
Study: 24554099
Drug: Fluoride toothpaste
Normalized name: sodium fluoride Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride toothpaste (1100 µg F/g, NaF/SiO2) used three times a day
Study: 20583555
Drug: Standard symptomatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard symptomatic therapy with cycloferon
Study: 12818975
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg and fentanyl 12.5 micro g
Study: 12818975
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg and fentanyl 12.5 micro g with morphine 125 micro g
Study: 11349388
Drug: Tianeptine 12.5
Normalized name: tianeptine 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine 12.5 mg and 37.5 mg
Study: 11349388
Drug: Mianserin 30
Normalized name: mianserin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 30 mg
Study: 2958914
Drug: 0.08 mg
Normalized name: mestranol 0.08 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08 mg ipratropium bromide
Study: 2958914
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg ipratropium bromide
Study: 2973571
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg ipratropium bromide
Study: 31113857
Drug: EzPAP lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EzPAP lung expansion therapy
Study: 29248711
Drug: Gingival augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gingival augmentation using CTG (group IIb)
Study: 29248711
Drug: Gingival augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gingival augmentation using CMX (group IIIb)
Study: 19274698
Drug: 4-combination (butterbur
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-combination (butterbur root, valerian root, passionflower herb, lemon balm leaf)
Study: 19274698
Drug: 3-combination (valerian
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-combination (valerian root, passionflower herb, lemon balm leaf)
Study: 16857467
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone at 0.015 mg/kg
Study: 16187470
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine at 0.1 mg/kg
Study: 15537997
Drug: Passive range
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive range of motion exercise and oral baclofen (control group)
Study: 9416930
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of morphine administered intravenously (group 1A)
Study: 9416930
Drug: No morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No morphine administered (group 1B)
Study: 8100189
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of roxatidine acetate twice daily
Study: 8100189
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of ranitidine twice daily
Study: 2174320
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during euglycemia
Study: 12631634
Drug: PTA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTA and endoprosthesis placement (Hemobahn endoprosthesis, W.L. Gore & Associates)
Study: 11990270
Drug: meperidine 10
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 10 mg
Study: 9089852
Drug: morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.15 mg
Study: 9089852
Drug: meperidine 10
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 10 mg plus morphine 0.15 mg
Study: 8250107
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg for 48 hr)
Study: 8250107
Drug: Clindamycin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (5 mg/kg twice a day for five days)
Study: 3513269
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (1 mg)
Study: 10094637
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 ml of normal saline)
Study: 30106527
Drug: Two-step 0.454%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-step 0.454% SnF₂ dentifrice followed by 3% H₂O₂ whitening gel, 1+1 minute sequential brushing (experimental)
Study: 30106527
Drug: 0.76% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.76% sodium monofluorophosphate dentifrice (Colgate Cavity Protection), twice daily use (control)
Study: 23801585
Drug: Transdermal rotigotine
Normalized name: rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rotigotine 2 to 16 mg/24 hours (mean dose, 12.8 mg/24 hours)
Study: 10931123
Drug: Theophylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (600 mg/24 h for 2 weeks, then 900 mg/24 h for 2 weeks)
Study: 9048676
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year of treatment with AEDs
Study: 9048676
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years of treatment with AEDs
Study: 1440306
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg twice a day
Study: 31170623
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg niacin
Study: 31170623
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sugar pill (placebo)
Study: 22073146
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (5000 IU cholecalciferol, one capsule daily for six weeks)
Study: 15841817
Drug: Prophylactic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatments scheduled every 3 months
Study: 15841817
Drug: Prophylactic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatments scheduled every 6 months
Study: 15841817
Drug: Prophylactic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatments scheduled every 18 months
Study: 15841817
Drug: Preventive treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatments provided during the 5-year interval
Study: 11532385
Drug: SR 57227A
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 57227A (2.5, 5, 10, 20, 40 mg o.d. and 20 mg b.i.d.)
Study: 8089287
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% doxepin cream
Study: 3378662
Drug: Lozenge with
Normalized name: Ascorbic Acid/European Elder/Zinc 90 MG-75 MG-15 MG Oromucosal Lozenge/Troche [ELDERBERRY ZINC LOZENGE WITH VITAMIN C]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge with 4 mg tyrothricin
Study: 3378662
Drug: Lozenge with
Normalized name: Ascorbic Acid/European Elder/Zinc 90 MG-75 MG-15 MG Oromucosal Lozenge/Troche [ELDERBERRY ZINC LOZENGE WITH VITAMIN C]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge with 10 mg tyrothricin
Study: 31383435
Drug: Sweet almond
Normalized name: sweet almond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweet almond syrup
Study: 26728648
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER (30-90 mg every 12 hours)
Study: 23439744
Drug: Sitagliptin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin with metformin (50/1000 mg once or twice daily) or sitagliptin (100 mg once daily, if intolerant to metformin)
Study: 12600402
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural self-esteem intervention as an adjunct to treatment as usual (TAU)
Study: 10699514
Drug: Lidocaine administered
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administered via Combitube (2.0 mg/kg, diluted with 0.9% saline to a minimum total volume of 10 mL)
Study: 10699514
Drug: Endotracheal tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotracheal tube administration of lidocaine (2.0 mg/kg)
Study: 8380131
Drug: Adjuvant cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy
Study: 8380131
Drug: CAP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP chemotherapy plus radiotherapy
Study: 9216851
Drug: CAP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP chemotherapy
Study: 6325612
Drug: Extraneous conversation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraneous conversation used as a distractor during skill demonstration of intramuscular injections (experimental group)
Study: 31074654
Drug: Passive heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Passive heat therapy (PHT)
Study: 30684325
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and sulphonylureas
Study: 20064698
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment success and relapse up to 3 months after the intervention
Study: 16282296
Drug: Sitamaquine 1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitamaquine 1.75 mg/kg/day
Study: 16282296
Drug: Sitamaquine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitamaquine 2.0 mg/kg/day
Study: 16282296
Drug: Sitamaquine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitamaquine 2.5 mg/kg/day
Study: 16282296
Drug: Sitamaquine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitamaquine 3.0 mg/kg/day
Study: 20304566
Drug: Overall (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (all doses)
Study: 7526528
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation alone and in combination with androgen deprivation therapy
Study: 7526528
Drug: Adjuvant therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapies (radiation, chemotherapy, androgen deprivation)
Study: 7526528
Drug: Morbidity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morbidity of adjuvant therapy
Study: 2917584
Drug: Terbutaline 2.5
Normalized name: terbutaline 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 2.5 mg t.d.s.
Study: 2917584
Drug: Terbutaline 2.5
Normalized name: terbutaline 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 2.5 mg t.d.s. (following chronic therapy)
Study: 241600
Drug: 3 g.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g. alclofenac daily
Study: 241600
Drug: 4.8 g.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 g. aspirin daily
Study: 241600
Drug: 3 g.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g. alclofenac tablets
Study: 241600
Drug: 3 g.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g. alclofenac capsules
Study: 29313279
Drug: ABT-767 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-767 (400 mg BID)
Study: 16137951
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplement containing isoflavones
Study: 12897218
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of retinol (209 micro mol) supplementation to mothers
Study: 10383510
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg or 30 mg
Study: 8682467
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (5 ml applied to the liver cut surface)
Study: 2067772
Drug: Peripheral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peripheral administration of oxytocin
Study: 6602542
Drug: Rifampin prophylaxis
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin prophylaxis (20 mg/kg/day in two doses for four days)
Study: 24490775
Drug: High fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluid overload (FO > 2.5 L) group
Study: 24490775
Drug: Low fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fluid overload (FO ≤ 2.5 L) group
Study: 23072576
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for TICH
Study: 20593910
Drug: Propranolol 3
Normalized name: HCTZ 25/PROPRANOLOL 30MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 3 mg/kg/day (adjusted to 2 mg/kg/day after first follow-up)
Study: 20593910
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 30 mg/kg/day (adjusted to 15 mg/kg/day after first follow-up)
Study: 11904111
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg daily (high dose)
Study: 11904111
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg daily (low dose)
Study: 11904111
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg daily (maintenance therapy)
Study: 11904111
Drug: Clotrimazole troches
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole troches 10 mg 4 times daily (maintenance therapy)
Study: 11904111
Drug: Fluconazole (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (maintenance therapy)
Study: 11904111
Drug: Clotrimazole (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (maintenance therapy)
Study: 7598917
Drug: Intranasal alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal alfentanil 0.54 mg
Study: 7598917
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) alfentanil 0.54 mg
Study: 2195085
Drug: cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: cognitive‐behavioral therapy
Study: 2195085
Drug: pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill placebo plus clinical management
Study: 665595
Drug: Decongestants
Normalized name: DECONGESTANTS,NASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestants
Study: 31267366
Drug: Glycopyrrolate/formoterol fumarate
Normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 μg, two inhalations per dose, twice-daily
Study: 31267366
Drug: Umeclidinium/vilanterol dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium/vilanterol dry powder inhaler (UV DPI) 62.5/25 μg, one inhalation, once-daily
Study: 25387363
Drug: ARA 290
Normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA 290 (4 mg)
Study: 17699311
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg/d (EPL50)
Study: 17699311
Drug: Eplerenone 100
Normalized name: eplerenone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 100 mg/d (EPL100)
Study: 17699311
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg/d (EPL50) and Eplerenone 100 mg/d (EPL100)
Study: 11165408
Drug: Single-agent gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent gemcitabine (1200 mg/m² on days 1 and 8, every 3 weeks)
Study: 11165408
Drug: Gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine + vinorelbine (gemcitabine at 1000 mg/m² and vinorelbine at 25 mg/m² on days 1 and 8, every 3 weeks)
Study: 7639368
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (5 mg in 10 mL of 0.9% saline)
Study: 30820008
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Growth Hormone and Aromatase Inhibitors (AI/GH)
Study: 26479711
Drug: Probiotic beverage
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic beverage (L. casei, 10^11 colony-forming units·day‐1)
Study: 24447510
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection into the gluteus medius tendon (GMT)
Study: 24447510
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection into the gluteus medius muscle (GMM)
Study: 24447510
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection into the adductor longus tendon (ALT)
Study: 24447510
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injections into GMT and GMM
Study: 24447510
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection into the ALT
Study: 24167727
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injections
Study: 23225029
Drug: Standardized assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized assessment incorporating the Clinician Administered PTSD Scale and the World Health Organization Disability Assessment Schedule‐II
Study: 15105105
Drug: Lopinavir-ritonavir at
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir-ritonavir at 800/200 mg BID (arm 1)
Study: 15105105
Drug: Lopinavir-ritonavir at
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir-ritonavir at 400/400 mg BID (arm 2)
Study: 15105105
Drug: Rifampin at
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin at 600 mg once daily
Study: 10955700
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (100 or 200 microg daily)
Study: 9101424
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day of an 85% concentrate of the ethyl esters of eicosapentenoic and docosahexaenoic acids for 6 weeks
Study: 9101424
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day of ethyl esters of corn oil fatty acids
Study: 9101424
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day of an 85% concentrate of the ethyl esters of eicosapentenoic and docosahexaenoic acids
Study: 8250314
Drug: Flumazenil 3
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil 3 mg
Study: 8267193
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg and 3 mg)
Study: 2860156
Drug: Local, intra-operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local, intra-operative administration of povidone-iodine
Study: 2860156
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic therapy
Study: 3113246
Drug: Misoprostol, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol, 800 micrograms to 1,200 micrograms daily in four to six divided doses, for periods of from one day to 17 months.
Study: 31190495
Drug: Biological feedback
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological feedback training of pelvic floor muscle
Study: 27750353
Drug: Intensive diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive diabetes screening and treatment program in Ward-A